RecruitingNot ApplicableNCT06423690

First in Human Study for the Assessment of Safety and Initial Performance of the EAS1 System

Snipe Medical First In Human Study

Sponsor

Snipe Medical

Enrollment

15 participants

Start Date

Nov 1, 2024

Study Type

INTERVENTIONAL

Conditions

Lung Cancer

Summary

A Prospective, open label, multi center, single arm, First in Human study to assess the safety and initial performance of EAS1 system for Irreversible Electroporation (IRE) ablation of lung cancer in subjects eligible for tumor resection

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria9

Adult male and female subjects (age ≥18 years at the date of informed consent signature)
Subject is capable and willing to provide an informed consent
Subjects with a known diagnosis of lung cancer at cT1a-T1c, cN0 stages
At least one pulmonary tumor (primary or metastasis) ≤ 30 mm in maximal diameter, as confirmed by the latest standard of care imaging (CT/MRI), performed preferably up to 30 days prior to screening
Subjects who are scheduled or deemed eligible by a thoracic surgeon for lung tumor resection
Subject is able and willing to comply with the study procedures and visits
There is ≥ 5mm of nodule-free lung parenchyma between target nodule and pleura or fissure, as confirmed by the latest standard of care imaging (CT/MRI), performed preferably up to 30 days prior to screening
ECOG 0-1
Stable doses of concomitant medications for at least four (4) weeks prior to enrollment

Exclusion Criteria22

An inability to provide informed consent
Subjects with contraindication for tumor resection
Subjects with life expectancy \<12 months
Target nodule is abutting main stem bronchus, main pulmonary vasculature, esophagus and/or trachea
Subjects with Forced Expiratory Volume (FEV1) \<50%
Total Lung Capacity (TLC)\< 80% of expected for age
Diffusing Capacity (DCO) \< 60% of expected
Oxygen saturation in free air of \<88%, or requiring more than 2 l/min oxygen to achieve saturation of 92%
PCO2 of ≥ 45mm/Hg
Subjects in exacerbations group E (high risk; ≥2 exacerbations per year or ≥1 requiring hospitalization and any level of symptoms)
Severe emphysema, Bullous Emphysema or chronic obstructive pulmonary disease (COPD) (GOLD III/IV)
Active and/or prolonged lung or bronchi infection, required an antibiotic treatment up to 21 days prior to screening and for more than 10 days of treatment
Known history or current evidence of a significant bronchiectasis
Evidence of lung Bullae the occupies more than one third of the lung intended for ablation
Previous surgery in the lung intended for ablation; thoracic major surgery at the side intended for ablation
Anticoagulation treatment that cannot be discontinued prior to the ablation, or a bleeding diathesis or platelets \<100 )K/µl)
Pregnant or breastfeeding female subjects or female subjects who plan pregnancy during participation in the study
Highly hypoxemic patients, according to investigator's discretion
Subjects with implanted metal or electronic thoracic devices objects (such as pacemaker) that cannot be removed prior to procedure
Subjects with contraindication for bronchoscopy
Participation in any other interventional clinical trial with medication, medical device and/or supplements within 30 days prior to informed consent signature
Any subject who, at the discretion of the investigator, may be jeopardized by study participation

Interventions

DEVICEEAS1 System

tumor ablation system in IRE method

Locations(3)

Meir Medical Center

Kfar Saba, Israel

University Hospital Complex of Salamanca

Salamanca, Spain

Royal Brompton Hospital

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06423690

Related Trials

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

NCT0661828763 locations

Study of Novel Treatment Combinations in Patients With Lung Cancer

NCT05633667100 locations